T. M. Kim

796 total citations
14 papers, 605 citations indexed

About

T. M. Kim is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, T. M. Kim has authored 14 papers receiving a total of 605 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 3 papers in Molecular Biology. Recurrent topics in T. M. Kim's work include Lung Cancer Treatments and Mutations (3 papers), Cancer Treatment and Pharmacology (3 papers) and Lymphoma Diagnosis and Treatment (3 papers). T. M. Kim is often cited by papers focused on Lung Cancer Treatments and Mutations (3 papers), Cancer Treatment and Pharmacology (3 papers) and Lymphoma Diagnosis and Treatment (3 papers). T. M. Kim collaborates with scholars based in South Korea, Ethiopia and France. T. M. Kim's co-authors include Dae Seog Heo, Dongwook Kim, Yoon Kyung Jeon, Bhumsuk Keam, Jake June-Koo Lee, Hye Sook Min, Se‐Hoon Lee, Seung‐Hoon Lee, Ho Yeong Lim and Youngil Koh and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

T. M. Kim

14 papers receiving 599 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
T. M. Kim South Korea 9 450 274 259 204 71 14 605
Gilad W. Vainer Israel 14 213 0.5× 257 0.9× 297 1.1× 245 1.2× 82 1.2× 28 700
Frédéric Dugay France 15 508 1.1× 291 1.1× 319 1.2× 202 1.0× 27 0.4× 25 723
Irene De Santo Italy 9 342 0.8× 394 1.4× 169 0.7× 213 1.0× 74 1.0× 13 692
Anna Wurtz United States 11 296 0.7× 278 1.0× 266 1.0× 127 0.6× 33 0.5× 19 595
Elio Gregory Pizzutilo Italy 10 266 0.6× 428 1.6× 152 0.6× 125 0.6× 54 0.8× 18 651
Hidenori Mizugaki Japan 14 231 0.5× 400 1.5× 207 0.8× 92 0.5× 38 0.5× 40 710
Milan Mangeshkar United States 9 369 0.8× 289 1.1× 217 0.8× 165 0.8× 17 0.2× 17 655
Youyou Xia China 14 208 0.5× 349 1.3× 227 0.9× 185 0.9× 32 0.5× 27 633
Qun-Li Shi China 18 265 0.6× 207 0.8× 273 1.1× 122 0.6× 29 0.4× 41 584
Ajia Presnell United States 8 287 0.6× 139 0.5× 215 0.8× 133 0.7× 46 0.6× 9 627

Countries citing papers authored by T. M. Kim

Since Specialization
Citations

This map shows the geographic impact of T. M. Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T. M. Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T. M. Kim more than expected).

Fields of papers citing papers by T. M. Kim

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T. M. Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T. M. Kim. The network helps show where T. M. Kim may publish in the future.

Co-authorship network of co-authors of T. M. Kim

This figure shows the co-authorship network connecting the top 25 collaborators of T. M. Kim. A scholar is included among the top collaborators of T. M. Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T. M. Kim. T. M. Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Belada, David, M. A. Kwiatek, Franck Morschhauser, et al.. (2025). 158 | EPCORE DLBCL‐3: FIXED‐DURATION EPCORITAMAB MONOTHERAPY IN OLDER (≥ 75 Y), ANTHRACYCLINE‐INELIGIBLE PATIENTS WITH PREVIOUSLY UNTREATED LARGE B‐CELL LYMPHOMA (LBCL). Hematological Oncology. 43(S3). 2 indexed citations
2.
Thompson, Carrie A., Neha Mehta–Shah, Christopher R. Flowers, et al.. (2023). Patient‐ versus clinician‐reported symptoms in the POLARIX study. Hematological Oncology. 41(S2). 414–416. 1 indexed citations
3.
Zinzani, Pier Luigi, Tatyana Feldman, Graham P. Collins, et al.. (2023). Encouraging complete responses (CRs) with CDK9 inhibitor AZD4573 in patients (pts) with relapsed/refractory (r/r) peripheral T‐cell Lymphoma (PTCL): Early trial analysis. Hematological Oncology. 41(S2). 568–569. 2 indexed citations
4.
Kim, T. M., et al.. (2016). A phase II trial of pazopanib in patients with metastatic alveolar soft part sarcoma. Annals of Oncology. 27. vi487–vi487. 3 indexed citations
5.
Lee, Se‐Hoon, Jake June-Koo Lee, Myung‐Ju Ahn, et al.. (2016). Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial. Annals of Oncology. 28(2). 292–297. 167 indexed citations
6.
Park, Chul‐Kee, Ji-Eun Kim, Do‐Hyun Nam, et al.. (2013). A practical scoring system to determine whether to proceed with surgical resection in recurrent glioblastoma. Neuro-Oncology. 15(8). 1096–1101. 59 indexed citations
7.
8.
Koh, Youngil, Ho Yeong Lim, Sun Young Rha, et al.. (2012). Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma. Annals of Oncology. 24(4). 1026–1031. 68 indexed citations
9.
Lee, J.-L., Jin‐Hee Ahn, Ho Yeong Lim, et al.. (2012). Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma. Annals of Oncology. 23(8). 2108–2114. 77 indexed citations
10.
Jang, Bo Gun, Yoon Kyung Jeon, T. M. Kim, et al.. (2011). EGFR Gene Copy Number Gain is Related to High Tumor SUV and Frequent Relapse after Adjuvant Chemotherapy in Resected Lung Adenocarcinoma. Japanese Journal of Clinical Oncology. 41(4). 548–554. 8 indexed citations
11.
12.
Jeon, Yoon Kyung, T. M. Kim, Jeong Eun Kim, et al.. (2009). Increased quantity of tumor-infiltrating FOXP3-positive regulatory T cells is an independent predictor for improved clinical outcome in extranodal NK/T-cell lymphoma. Annals of Oncology. 20(10). 1688–1696. 41 indexed citations
13.
Kim, T. M., et al.. (2005). Adjuvant 5-FU/cisplatin (FP) chemotherapy in curatively resected stage IIIA-IV M0 gastric cancer. Journal of Clinical Oncology. 23(16_suppl). 4214–4214. 1 indexed citations
14.
Lee, Jeonghee, T. M. Kim, Su Jong Yu, et al.. (2004). Single-agent Capecitabine in Patients with Metastatic Colorectal Cancer Refractory to 5-Fluorouracil/Leucovorin Chemotherapy. Japanese Journal of Clinical Oncology. 34(7). 400–404. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gilad W. Vainer Breakdown of academic impact, for papers by Frédéric Dugay Breakdown of academic impact, for papers by Irene De Santo Breakdown of academic impact, for papers by Anna Wurtz Breakdown of academic impact, for papers by Elio Gregory Pizzutilo Breakdown of academic impact, for papers by Hidenori Mizugaki Breakdown of academic impact, for papers by Milan Mangeshkar Breakdown of academic impact, for papers by Youyou Xia Breakdown of academic impact, for papers by Qun-Li Shi Breakdown of academic impact, for papers by Ajia Presnell
Rankless by CCL
2026